Skip to main content
SpringerLink
Log in

Kinetic resistance to anticancer agents

  • Published:
Cytotechnology Aims and scope Submit manuscript

Abstract

Adherent epithelial cancer cells, such as colon cancer cells, are much more resistant to anthracyclines and to many other major anticancer agents when the cell population reaches confluence. Our purpose is to analyze the mechanisms of this confluence dependent resistance (CDR) that is probably the major cause of the natural resistance of solid tumors to chemotherapy. Some drugs (anthracyclines, etoposide and vincristine) but not others (cisplatin, melphalan and 5-fluorouracil) accumulate less in confluent than in nonconfluent cells. A decrease of the passive transmembrane drug transport in confluent cells is associated to a reduced membrane fluidity. However, the predominant mechanism of CDR is an increase in the intrinsic resistance of the DNA to the drug-induced damage. This mechanism is now relatively well understood for anthracyclines and etoposide that act mainly through an inhibition of the topoisomerase II: as the enzyme level is low in slowly proliferating confluent cells, the number of drug-induced DNA strand breaks is lower than in rapidly growing nonconfluent cells which highly express the topoisomerase II gene. Mechanisms of CDR for the other drugs are less clear and could involve an increase in the ability to repair damaged DNA. Attempts to circumvent CDR could consist in the stimulation of the cell proliferation by hormones or growth factors, or in the recruitment of quiescent cells into the S and G2 phases by previous treatment of confluent cells with infratoxic concentration of DNA-damaging agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Salmon SE, Alberts DS, Meyskens FL, Durie BGM (1980) Clinical correlations ofin vitro drug sensitivity. In: Salmon SE (ed) Cloning of Human Tumor Stem Cells. New York: AR Liss, 223–245.

    Google Scholar 

  2. Sutherland RM (1988) Cell and environmental interactions in tumor microregions: the multicell spheroid model. Science 240: 177–184.

    Google Scholar 

  3. Tannock IF (1968) The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer 22: 258–273.

    Google Scholar 

  4. Kerr DJ, Kaye SB (1987) Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol 19:1–5.

    Google Scholar 

  5. Barranco SC, Novak JK (1974) Survival responses of dividing and nondividing mammalian cells after treatment with hydroxyurea, arabinosylcytosine, or adriamycin. Cancer Res 34: 116–118.

    Google Scholar 

  6. Twentyman PR, Bleehen NM (1975) Changes in the sensitivity to cytotoxic agents occurring during the life history of monolayer cultures of a mouse tumor cell line. Br J Cancer 31: 417–423.

    Google Scholar 

  7. Chambers SH, Bleehen NM, Watson JV (1984) Effect of cell density on intracellular adriamycin concentration and cytotoxicity in exponential and plateau phase EMT6 cells. Br J Cancer 49: 301–306.

    Google Scholar 

  8. Drewinko B, Patchen M, Yan LY, Barlogie B (1981) Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res 41: 2328–2333.

    Google Scholar 

  9. Epifanova OI, Smolenskaya IN, Polunovsky VA (1978) Responses of proliferating and nonproliferating Chinese hamster cells to cytotoxic agents. Br J Cancer 37: 377–385.

    Google Scholar 

  10. Valeriote F, Van Putten L (1975) Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res. 35: 2619–2630.

    Google Scholar 

  11. Madoc-Jones H, Bruce WR (1967) Sensitivity of leukemic cells in exponential and stationary phase to 5-fluorouracil. Nature 215: 302–303.

    Google Scholar 

  12. Soranzo C, Ingrosso A (1988) A comparative study of the effects of anthracycline derivatives on human adenocarcinoma cell line (LoVo) grown as a monolayer and as spheroids. Anticancer Res 8: 369–373.

    Google Scholar 

  13. Born R, Eichholtz-Wirth H (1981) Effect of different physiological conditions on the action of adriamycin on Chinese hamster cellsin vitro. Br J Cancer 44: 241–246.

    Google Scholar 

  14. Smith E, Stratford IJ, Adams GE (1980) Cytotoxicity of adriamycin on aerobic and hypoxic Chinese hamster V 79 cellsin vitro. Br J Cancer 41: 568–573.

    Google Scholar 

  15. Duncan MR, Robinson MJ, Dell'Orco RT (1982) Exit of human diploid cells from low serum quiescence. Cell Biol Int Rep 6: 369–377.

    Google Scholar 

  16. Chauffert B, Martin F, Caignard A, Jeannin JF, Leclerc A (1984) Cytofluorescence localization of adriamycin in resistant colon cancer cells. Cancer Chemother Pharmacol 13: 14–18.

    Google Scholar 

  17. Petit JM, Chauffert B, Dimanche-Boitrel MT, Genne P, Duchamp O, Martin F (1993)mdr-1 gene-expression and villin synthesis in a colon cancer cell line differentiated by sodium butyrate. Anticancer Res, in press.

  18. Chauffert B, Martin MS, Hamman A, Michel MF, Martin F (1986) Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cellsin vitro andin vivo. Cancer Res 46: 825–830.

    Google Scholar 

  19. Goldstein LJ, Gottesman MM, Pastan I (1991) Expression of themdr-1 gene in human tumors. In: Ozols RF (ed) Molecular and Clinical Advances in Anticancer Drugs. New York: Kluwer Academic Publishers, 101–120.

    Google Scholar 

  20. Siegfied JM, Burke TG, Tritton TR (1985) Cellular transport of anthracyclines by passive diffusion: implications for drug resistance. Biochem Pharmacol 34: 593–598.

    Google Scholar 

  21. Epifanova OI (1984) Differential sensitivity of proliferating and resting cells to antitumour drugs and its probable causes. In: Lapis K and Jeney A (eds) Regulation of control cell proliferation. Budapest: Akademia Kiado, 434–457.

    Google Scholar 

  22. Pelletier H, Millot JM, Chauffert B, Manfait M, Genne P, Martin F (1990) Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion. Cancer Res 50: 6626–6631.

    Google Scholar 

  23. Goldenberg GJ, Lyons RM, Lepp JA, Vanstone CL (1971) Sensitivity to nitrogen mustard as a function of transport activity and proliferative rate in L 5178Y lymphoblasts. Cancer Res 31: 1616–1618.

    Google Scholar 

  24. Dimanche-Boitrel MT, Pelletier H, Genne P, Petit JM, Le Grimellec C, Canal P, Ardiet C, Bastian G, Chauffert B (1992) Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer 50: 677–682.

    Google Scholar 

  25. Magin RL, Niesman MR, Bacic G (1990) Influence of fluidity on membrane permeability: correspondence between studies of membrane models and simple biological systems. In: Aloia RC, Curtain CC and Gordon LM (eds) Membrane Transport and Information Storage. New York: AR Liss, 221–238.

    Google Scholar 

  26. Liu LF (1990) Topoisomerase poisons in cell killing and drug resistance. In: Mihich E (ed) Drug-resistance Mechanisms and Reversal. Rome: John Libbey CIC, 251–263.

    Google Scholar 

  27. Osheroff N (1989) Biochemical basis for the interations of type I and II topoisomerase inhibitors with DNA. Pharmacol Ther 41: 223–241.

    Google Scholar 

  28. Osheroff N (1989) Effect of antineoplastic agents on the DNA cleavage/relegation reaction of eukaryotic topoisomerase II: inhibition of DNA relegation by etoposide. Biochemistry 28: 6157–6160.

    Google Scholar 

  29. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 266: 466–468.

    Google Scholar 

  30. Hancock R, Charron M, Lambert H, Lemieux M, Pankov R, Pepin N (1990) Topoisomerase II as a target of antitumor agents. Pharmacol Ther (suppl) 10: 119–137.

    Google Scholar 

  31. Duguet M, Lavenot C, Harper F, Mirambeau G, De Recondo AM (1983) DNA topoisomerase from rat liver: physiological variations. Nucleic Acid Res 11: 1059–1075.

    Google Scholar 

  32. Taudou G, Mirambeau G, Lavenot C, Vermeersch J, Duguet M (1984) DNA topoisomerase activities in concanavalin A-stimulated lymphocytes. FEBS 176: 431–435.

    Google Scholar 

  33. Heck MMS, Hittelman WN, Earnshaw WC (1988) Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85: 1086–1088.

    Google Scholar 

  34. Zwelling LA, Estey E, Silberman I, Doyle S, Hittelman W (1987) Effect of cell proliferation and chromatin conformation on intercalation induced, protein associated DNA cleavage in human brain tumor cells and human fibroblasts. Cancer Res 47: 251–257.

    Google Scholar 

  35. Nelson WG, Liu LF, Coffey DS (1986) Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature 322: 187–189.

    Google Scholar 

  36. Chow KC, Ross WE (1987) Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol 7: 3119–3123.

    Google Scholar 

  37. Estey E, Adlakaha RC, Hittelman WN, Zwelling LA (1987) Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity. Biochemistry. 26: 4338–4344.

    Google Scholar 

  38. Sullivan DM, Glisson BS, Hodges PK, Smallwood-Kentro S, Ross WE (1986) Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 25: 2248–2256.

    Google Scholar 

  39. Sullivan DM, Latham MD, Ross WE (1987) Proliferation-dependent topoisomerase II content as a determinant of anti-neoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res 47: 3973–3979.

    Google Scholar 

  40. Robbie MA, Baguley BC, Denny WA, Gavin JB, Wilson WR (1988) Mechanism of resistance of noncycling mammalian cells to 4′-(9-acridinylamino) methanesul-fon-m anisidide: comparison of uptake, metabolism and DNA-breakage in log- and plateau-phase Chinese hamster fibroblast culture. Cancer Res 48: 310–319.

    Google Scholar 

  41. Davies SM, Robson CN, Davies SL, Hickson ID (1988) Nuclear topoisomerase II levels correlates with the sensivitity of mammalian cells to intercalating agents and epipodophylotoxins. J Biol Chem 263: 17724–17729.

    Google Scholar 

  42. Kung AL, Zetterberg A, Sherwood SW, Schimke RT (1990) Cytotoxic effect of cell cycle specific agents: result of cell cycle perturbation. Cancer Res 50: 7307–7317.

    Google Scholar 

  43. Eastman A, Barry MA (1992) The origins of DNA breaks: a consequence of DNA damage, DNA repair or apoptosis. Cancer Investigation 10: 229–240.

    Google Scholar 

  44. Pera MF, Rawlings CJ, Roberts JJ (1981) The role of DNA repair in the recovery of human cells from cisplatin-induced toxicity. Chem Biol Interact 37: 245–261.

    Google Scholar 

  45. Fraval HNA, Roberts JJ (1979) Excision repair ofcis-diamminedichloro-platinum(II)-induced damage of Chinese hamster cells. Cancer Res 39: 1793–1797.

    Google Scholar 

  46. Sorenson CM, Eastman A (1988) The mechanism ofcis-diamminedichloro-platinum(II)-induced cytotoxicity: the role of G2 arrest and DNA double strand breaks. Cancer Res 48: 4484–4488.

    Google Scholar 

  47. Barry MA, Behnke CA, Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplatin, other anticancer agents drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353–2362.

    Google Scholar 

  48. Roberts JJ, Brent TP, Crathorn AR (1971) Evidence of the inactivation and repair of the mammalian DNA template after alkylation by Mustard gas. Eur J Cancer 7: 515–5524.

    Google Scholar 

  49. Mendonca MS, Rodriguez A, Alpen EL (1990) Differential repair of potentially lethal damage in exponentially growing and quiescent cells. Radiation Res 122: 38–43.

    Google Scholar 

  50. Dikomey E (1990) Induction and repair of DNA strand breaks in X-irradiated proliferating and quiescent cells. Int J Radiat Biol 57: 1169–1182.

    Google Scholar 

  51. Baral E, Auer G (1990)In vitro effect of doxorubicin on nonproliferating and proliferating epithelial cells. Int J Radiat Oncol Biol Phys 19: 963–965.

    Google Scholar 

  52. Geleziunas R, McQuillan A, Malapetsa A, Hutchinson M, Kopriva D, Wainberg MA, Hiscott J, Bramson J, Panasci L (1991) Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst 83: 557–564.

    Google Scholar 

  53. Cybulsky AV, Bonventre J, Quigg RJ, Wolfe LS, Samant DJ (1990) Extracellular matrix regulates proliferation and phospholipid turnover in glomerular epithelial cells. Am J Physiol 259: F326-F337.

    Google Scholar 

  54. Galkina SI, Sudina GF, Margoiis LB (1992) Cell-cell contacts alter intracellular pH. Exp Cell Res 200: 211–214.

    Google Scholar 

  55. Ohtsubo M, Roberts JM (1993) Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science. 259: 1908–1912.

    Google Scholar 

  56. Wieser RJ, Schutz S, Tschank G, Thoams H, Dienes HP, Oesch F (1990) Isolation and characterization of a 60 to 70 kDa plasma membrane glycoprotein involved in the contact-dependent inhibition of growth. J Cell Biol 111: 2681–2692.

    Google Scholar 

  57. Skipper HE (1986) Experimental adjuvant chemotherapy: an overview. Recent result. Cancer Res 103: 6–29.

    Google Scholar 

  58. De Vita VT (1983) Implications for surgical adjuvant treatment of cancer. Cancer 51: 1209–1220.

    Google Scholar 

  59. Bonnadona G (1989) Conceptual and practical advances in the management of breast cancer. J Clin Oncol 7: 1380–1397.

    Google Scholar 

  60. Cohen C (1985) Surgical considerations in ovarian cancer. Semin Oncol 12: 53–56.

    Google Scholar 

  61. Durand RE (1986) Chemosensitivity testing in V 79 spheroids: role of drug delivery and cellular microenvironment. J Natl Cancer Inst 77: 247–252.

    Google Scholar 

  62. Conte PF, Pronzato P, Rubagotti A, Alama A (1987) Conventional versus cytokinetic polychemotherapy with estrogenic recritment in metastatic breast cancer: results of a randomized cooperative trial. J Clin Oncol 5: 339–347.

    Google Scholar 

  63. Morris DL, Watson SA, Durrant IG, Harrison JD (1989) Hormonal control of gastric and colorectal cancer in man. Gut 30: 425–429.

    Google Scholar 

  64. Schabel FM (1969) The use of tumor growth kinetics in planning “curative” chemotherapy of advanced solid tumors. Cancer Res 29: 2384–2389.

    Google Scholar 

  65. Kal W (1973) Proliferation behavior of proliferating and quiescent cells in a rat rhabdomyosarcoma after irradiation as determined by DNA measurements. Eur J Cancer 9: 753–756.

    Google Scholar 

  66. Braunschweiger PG, Schiffer LM (1980) Therapeutic implications of cell kinetic changes after cyclophosphamide treatment in spontaneous and transplantable mammary tumors. Cancer Treat Rep 62: 727–733.

    Google Scholar 

  67. Braunschweiger PG, Schiffer LM (1980) Cell kineticdirected sequential chemotherapy with cyclophosphamide and adriamycin in T1699 mammary tumor. Cancer Res 40: 737–743.

    Google Scholar 

  68. Burke PJ, Vaughan WP, Karp JE (1980) A rational for sequential high-dose chemotherapy of leukemia, timed to coincide with induced tumor proliferation. Blood 55: 960–968.

    Google Scholar 

  69. Aglietta M, Colly L (1979) Relevance of recruitment-synchronization in the scheduling of 1-β-D-arabinosylcytosine in a slow-growing acute myeloid leukemia of the rat. Cancer Res 39: 2727–2732.

    Google Scholar 

  70. Karp JE, Humphrey RL, Burke PJ (1981) Timed sequential chemotherapy of cytoxan-refractory multiple myeloma with cytoxan and adriamycin based on induced proliferation. Blood 57: 468–475.

    Google Scholar 

  71. Salmon SE (1975) Expansion of the growth fraction in multiple myeloma with alkylating agents. Blood 45: 119–123.

    Google Scholar 

  72. Rosso R, Alama A, Repetto L, Conte PF (1990) Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian cancer. Cancer Chemother Pharmacol 26: 43–44.

    Google Scholar 

  73. Painter RB (1986) Inhibition of mammalian cell DNA synthesis by ionizing radiations. Int J Radiat Biol 49: 771–781.

    Google Scholar 

  74. Russev G, Boulikas T (1992) Repair of transcriptionally active and inactive genes during S and G2 phases of the cell cycle. Eur J Biochem 204: 267–272.

    Google Scholar 

  75. Weisberg TF (1992) Cisplatin treatment of cultured tumor cells results in prolongation of S Phase: potential clinical implications. Abst 367, Proc ASCO.

  76. Erba E, Sen S, Lorico A, D'Incalci M (1992) Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with nontoxic concentrations of methotrexate or aphidicolin. Eur J Cancer 28: 66–71.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM 252, Faculty of Medicine, F-21033, Dijon, France

    Marie-Thérèse Dimanche-Boitrel, Carmen Garrido & Bruno Chauffert

Authors
  1. Marie-Thérèse Dimanche-Boitrel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carmen Garrido
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruno Chauffert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dimanche-Boitrel, MT., Garrido, C. & Chauffert, B. Kinetic resistance to anticancer agents. Cytotechnology 12, 347–356 (1993). https://doi.org/10.1007/BF00744672

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00744672

Key words

Search

Navigation